Literature DB >> 3885063

Intrinsic stiffening of red blood cells as the fundamental cause of diabetic nephropathy and microangiopathy: a new hypothesis.

L O Simpson.   

Abstract

It is proposed that stiffened red cells can interfere with normal microvascular and glomerular function. In diabetics intrinsic stiffening of red cells is intensified during poor metabolic control when plasma osmolarity is increased. Hypoxia, acidosis, catecholamines and other changes in red cell environment also increase red cell stiffness. Exercise proteinuria may help to identify individuals with the greatest intrinsic stiffening of red cells which appears to be due to the disposition of spectrin molecules rather than to changes in the lipid bilayer. Stiffened red cells may impede blood flow in the microcirculation and stimulate an autoregulated vasodilation which increases perfusion pressure, enhancing transudation. In the absence of vasodilation, stasis will lead to vascular occlusion and localised ischaemic necrosis. If diabetic microangiopathy is caused by abnormal haemorheology then the possibility exists that the complications of diabetes might be alleviated or prevented by agents which enhance red cell flexibility and improve blood rheology.

Entities:  

Mesh:

Year:  1985        PMID: 3885063     DOI: 10.1159/000183403

Source DB:  PubMed          Journal:  Nephron        ISSN: 1660-8151            Impact factor:   2.847


  10 in total

1.  Intermittent clinical proteinuria and renal function in diabetes.

Authors: 
Journal:  Br Med J (Clin Res Ed)       Date:  1986-02-22

2.  Normal variations in rate of albumin excretion and albumin to creatinine ratios in non-diabetic children.

Authors:  L O Simpson
Journal:  Br Med J (Clin Res Ed)       Date:  1985-11-09

3.  Nisoldipine improves the impaired erythrocyte deformability correlating with elevated intracellular free calcium-ion concentration and poor glycaemic control in NIDDM.

Authors:  J Fujita; K Tsuda; T Takeda; L Yu; S Fujimoto; M Kajikawa; M Nishimura; N Mizuno; Y Hamamoto; E Mukai; T Adachi; Y Seino
Journal:  Br J Clin Pharmacol       Date:  1999-05       Impact factor: 4.335

4.  No decreased erythrocyte deformability in type 1 (insulin-dependent) diabetes, either by filtration or by ektacytometry.

Authors:  N H Schut; E C van Arkel; M R Hardeman; H J Bilo; R P Michels; J Vreeken
Journal:  Acta Diabetol       Date:  1993       Impact factor: 4.280

5.  Pentoxifylline, total urinary protein excretion rate and arterial blood pressure in long-term insulin-dependent diabetic patients with overt nephropathy.

Authors:  S B Solerte; M Fioravanti; A L Patti; N Schifino; M G Zanoletti; V Inglese; E Ferrari
Journal:  Acta Diabetol Lat       Date:  1987 Jul-Sep

6.  Metal-activated C-peptide facilitates glucose clearance and the release of a nitric oxide stimulus via the GLUT1 transporter.

Authors:  J A Meyer; J M Froelich; G E Reid; W K A Karunarathne; D M Spence
Journal:  Diabetologia       Date:  2007-10-27       Impact factor: 10.122

7.  Pentoxifylline, albumin excretion rate and proteinuria in type I and type II diabetic patients with microproteinuria. Results of a short-term randomized study.

Authors:  S B Solerte; M Fioravanti; A Bozzetti; N Schifino; A L Patti; P Fedele; C Viola; E Ferrari
Journal:  Acta Diabetol Lat       Date:  1986 Apr-Jun

8.  Association between erythrocyte dynamics and vessel remodelling in developmental vascular networks.

Authors:  Qi Zhou; Tijana Perovic; Ines Fechner; Lowell T Edgar; Peter R Hoskins; Holger Gerhardt; Timm Krüger; Miguel O Bernabeu
Journal:  J R Soc Interface       Date:  2021-06-23       Impact factor: 4.118

9.  Therapeutic effects of calcium dobesilate on diabetic nephropathy mediated through reduction of expression of PAI-1.

Authors:  Xiaoqian Zhang
Journal:  Exp Ther Med       Date:  2012-10-19       Impact factor: 2.447

10.  Assesment of Conjunctival Microangiopathy in a Patient with Diabetes Mellitus Using the Retinal Function Imager.

Authors:  Nicole Stuebiger; William Smiddy; Jianhua Wang; Hong Jiang; Delia Cabrera DeBuc
Journal:  J Clin Exp Ophthalmol       Date:  2015-02
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.